Harrow Health Inc Stock Price, News & Analysis

Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the B. Riley Securities 25th Annual Investor Conference in Marina del Rey, CA on May 21-22, featuring a fireside chat and one-on-one investor meetings. Additionally, management will participate in the Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on May 28, conducting one-on-one and small group investor meetings. Neither conference event will be webcast.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will release its Q1 Letter to Stockholders on its website harrow.com. A conference call and live webcast to discuss the results is scheduled for May 9, 2025, at 8:00 a.m. Eastern Time. Investors can access the call via webcast through Harrow's website or by telephone after registering through the provided link. A replay of the webcast will be available on the company's website for one year.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has partnered with Harrow (HROW) to launch an authorized generic version of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). The ophthalmic medication is designed to treat and relieve bacterial eye infections. According to IQVIA data from January 2025, Maxitrol® and its generic equivalents generated annual sales of $20.8 million in the U.S. market.

Harrow (HROW) has expanded its VEVYE® Access for All (VAFA) program to include current Klarity-C Drops® patients, offering VEVYE at $59 per bottle. The expansion allows over 25,000 U.S. patients to convert their Klarity-C prescriptions to FDA-approved VEVYE, a cyclosporine ophthalmic solution 0.1% for dry eye disease treatment.

The program eliminates access barriers like prior authorization and reimbursement delays, while providing free home delivery and a money-back guarantee. Patients can choose between insurance coverage or Harrow's cash price. Klarity-C prescribers can transfer prescriptions through PhilRx's platform in under 5 minutes.

Harrow (HROW) reported strong financial results for Q4 and full-year 2024. The company achieved record Q4 revenues of $66.8 million, up 84% year-over-year, while full-year 2024 revenues reached $199.6 million, representing a 53% increase from 2023.

Q4 2024 highlights include GAAP net income of $6.8 million and Adjusted EBITDA of $22.5 million. For the full year 2024, the company reported a GAAP net loss of $(17.5) million and Adjusted EBITDA of $40.3 million.

Notable operational achievements include over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions. The company announced its VEVYE Access for All program to drive market share expansion in 2025. Additionally, TRIESENCE received transitional pass-through approval, significantly expanding its market opportunity. Management provided 2025 revenue guidance of 'more than $280 million,' projecting over 40% growth.

Harrow (HROW), a leading North American eyecare pharmaceutical company, has scheduled the release of its fourth quarter and audited financial results for the year ended December 31, 2024. The announcement will be made after market close on March 27, 2025.

The company will publish its fourth quarter Letter to Stockholders on its website's Investors section. A conference call and live webcast are scheduled for March 28, 2025, at 8:00 a.m. Eastern Time to discuss results and provide business updates. Interested participants can access the conference via webcast through Harrow's website or register in advance for telephone access. A replay will be archived on the company's website for one year.

Harrow (HROW) has received approval from the Centers for Medicare & Medicaid Services (CMS) for transitional pass-through reimbursement status for TRIESENCE®, their preservative-free synthetic corticosteroid.

Starting April 1, 2025, TRIESENCE will receive separate reimbursement outside surgical bundled payments in both Ambulatory Surgery Centers and Hospital Outpatient Departments for three years. CMS will reimburse at Average Sales Price plus 6%. The drug previously received a permanent J-Code (J3300), making it the only preservative-free synthetic corticosteroid with separate reimbursement across all traditional care settings.

TRIESENCE is FDA-approved for visualization during vitrectomy and treating ocular inflammatory conditions unresponsive to topical corticosteroids. The drug is available in 40mg/mL single-use vials through major pharmaceutical distributors.

Harrow (HROW) has announced a delay in releasing its audited financial results for Q4 and full-year 2024, as their new independent auditor requires additional time to complete the audit process. The company emphasizes this delay is not due to any disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.

CEO Mark L. Baum confirmed that Harrow has successfully met the annual leverage ratio term under their senior secured loan agreement, avoiding the issuance of warrants to lenders. The company has provided revenue guidance for 2025 of over $280 million, with growth expected to be primarily driven by their higher-margin branded business.